pharma · Hemophagocytic lymphohistiocytosis (HLH) · Multiple sclerosis
PARItec
Pari Pharma GmbH
Pari Pharma is a pharma organization headquartered in Starnberg, DE. Primary therapeutic focus areas include Hemophagocytic lymphohistiocytosis (HLH), Multiple sclerosis, Acute Myocardial Infarction, Familial Mediterrane
Starnberg, DE HQ
28 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Starnberg, DE
- Employees
- 28
- Programs
- 248
- Drugs
- 362
- Patents
- 0
MUNC13.4-CD34 suspension, MUNC13.4-T3 suspension
Phase 1 · small molecule · Familial Hemophagocytic Lymphohistiocytosis (FHL)
MUNC13.4-CD34 suspension, MUNC13.4-T3 suspension for Familial Hemophagocytic Lymphohistiocytosis (FHL) is a Phase 1 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).
Internal code APHP240201
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Pari Pharma GmbH
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Familial Hemophagocytic Lymphohistiocytosis (FHL)
- Status
- active
- Trials
- 1